News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Expands Biometrics Capabilities by Acquiring SQN Clinical

Builds on a shared pedigree of data management, statistics and programming excellence across all phases of clinical trials

 

SOUTHBOROUGH, MA – February 25, 2021 – Veristat, a scientific-minded global clinical research organization (CRO), announced today the expansion of its biometrics capacities by acquiring SQN Clinical, a market-leader in the healthcare arena and one of the largest data focused specialty contract research companies in Europe. 

Read More

Veristat Launches Business Operations in Spain and Names Dr. Montserrat Barceló to Vice President, Europe

Leading the Organic and Acquisition Growth of Veristat Operations Throughout Europe

 

Read More

Veristat Helps Antibe Therapeutics Complete Their Phase IIB Study During COVID-19

In early 2019, Veristat helped Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346. To date, this is one of the largest studies completed in Canada consisting of 360 patients with osteoarthritis (“OA”) of the knee, across 40 clinical sites.   

Read More

Veristat Supports Antibe Therapeutics for Pain and Inflammation Study

Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346.   The study will run in Canada and is expected to conclude in December 2018.

Read More